Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04260802
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:39.223948+00:00
Published At
2026-01-12T00:00:00+00:00
Record Updated At
2026-01-12
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Cancer", "Neoplasms", "Metastatic Cancer", "Triple Negative Breast Cancer", "Gastric Cancer", "Cervical Cancer", "Ovarian Cancer", "Hepatocellular Carcinoma", "Squamous Cell Carcinoma of Head and Neck", "Urothelial Carcinoma", "Urothelial Neoplasm", "Non Small Cell Lung Cancer", "Renal Cell Carcinoma", "Locally Advanced Solid Tumor", "Locally Advanced Malignant Neoplasm", "Squamous Cell Carcinoma", "Sarcoma", "Merkel Cell Carcinoma", "Bladder Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-12"
protocolSection.identificationModule.nctId
"NCT04260802"
protocolSection.identificationModule.officialTitle
"A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers"
protocolSection.statusModule.overallStatus
"TERMINATED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Cancer (protocolSection.conditionsModule.conditions)
  • Neoplasms (protocolSection.conditionsModule.conditions)
  • Metastatic Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Squamous Cell Carcinoma of Head and Neck (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Urothelial Neoplasm (protocolSection.conditionsModule.conditions)
  • Non Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Locally Advanced Solid Tumor (protocolSection.conditionsModule.conditions)
  • Locally Advanced Malignant Neoplasm (protocolSection.conditionsModule.conditions)
  • Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Sarcoma (protocolSection.conditionsModule.conditions)
  • Merkel Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Bladder Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.